YB1 was presented as a protein playing a crucial role in tumor cell chemoresistance and a beneficial role of combining therapy with PARP inhibitors and DNA damaging agents was suggested as a potential answer to YB1 activity (Alemasova et al., 2018). Here, YBX1 is linked to neoplasm.